TrialJournal for immunotherapy of cancer2021

Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.

Yang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.